Obudai Egeszseguegyi Centrum Kft. — Clinical Trial Site

124 Registered trials

64 Currently recruiting

Organisation

Obudai Egeszseguegyi Centrum Kft.

Location

Budapest III, Hungary

Identifier

ORG-100039696

Address

Zarda Utca 11-13, 8900, Hungary

Departments

-
#2624
#2626
#2627
#2628
#7309
9210
Belgyogyaszat-Kardiologia
Cardiology
Department of Dermatology
Department of Psychiatry
Department of Rheumatology
Gasztroenterologia
HU10006
n.a.
N/A
NA
Obstetrics and Gynecology
Óbudai Egészégügyi Centrum Kft.
Obudai Egeszsegugyi Centrum
Óbudai Egészségügyi Centrum Kft.
Private Clinic
Private practice
Rheumatology
Zalaegerszeg

Clinical trials at this site (124)

Search interface

A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil… Not authorised

2022-501361-44-00 Adult patients of either gender with active moderate to 5
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending

2025-521037-86-00 Immune system diseases 5
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden… Pending

2025-523259-72-00 Hidradenitis Suppurativa (HS) 5
J6Z-MC-IIBD - A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Stud… Pending

2025-524112-11-00 J6Z-MC-IIBD - Colitis, Ulcerative Crohn Disease J6Z-M 4
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combination for Inflammatory Bowel Disease Pending

2025-524640-35-00 Ulcerative colitis (Inflammatory Bowel Disease) 4
A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3) Recruiting

2025-524404-29-00 Ulcerative Colitis, Active Moderate 4 2026-06-24
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti… Recruiting

2025-521038-27-00 Immune system diseases 5 2026-06-23
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Recruiting

2025-521950-41-00 severe uncontrolled asthma 5 2026-06-05
Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Recruiting

2024-519994-20-00 Agitation Associated with Alzheimer’s Disease 5 2026-06-01
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Recruiting

2025-521590-13-00 Moderately to Severely Active Crohn’s Disease 5 2026-05-28
AMAZE 8: A research study investigating how well the medicine NNC0487-0111 compared to semaglutide helps people with excess body weight and … Recruiting

2024-520446-31-00 Participants with overweight or obesity, and type 2 dia 5 2026-05-27
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting

2025-524001-33-00 Graves’ Disease 4 2026-05-22
Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519423-24-00 Major Depressive Disorder 5 2025-10-07
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w… Recruiting

2023-507853-13-00 Ulcerative Colitis 4 2025-02-25
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-505121-14-00 Moderate to Severe Plaque Psoriasis 5 2024-01-18
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Recruiting

2025-523510-87-00 Obesity 5 2026-06-25
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Recruiting

2025-523486-17-00 Obesity 5 2026-06-16
EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E… Recruiting

2025-523552-31-00 Systemic Lupus Erythematosus 5 2026-05-07